Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)

被引：45

作者：

Bellini, Angela ^{[1
,2
,3
]}

Poetschger, Ulrike ^{[4
,5
]}

Bernard, Virginie ^{[6
]}

Lapouble, Eve ^{[7
]}

Baulande, Sylvain ^{[6
]}

Ambros, Peter F. ^{[5
]}

Auger, Nathalie ^{[8
,9
]}

Beiske, Klaus ^{[10
,11
]}

Bernkopf, Marie ^{[5
]}

Betts, David R. ^{[12
]}

Bhalshankar, Jaydutt ^{[1
,2
,3
]}

Bown, Nick ^{[13
]}

de Preter, Katleen ^{[14
]}

Clement, Nathalie ^{[1
,2
,3
]}

Combaret, Valerie ^{[15
]}

de Mora, Jaime Font ^{[16
]}

George, Sally L. ^{[17
]}

Jimenez, Irene ^{[1
,2
,3
]}

Jeison, Marta ^{[18
]}

Marques, Barbara ^{[19
]}

Martinsson, Tommy ^{[20
]}

Mazzocco, Katia ^{[21
]}

Morini, Martina ^{[22
]}

Muehlethaler-Mottet, Annick ^{[23
,24
]}

Noguera, Rosa ^{[25
]}

Pierron, Gaelle ^{[7
]}

Rossing, Maria ^{[26
]}

Taschner-Mandl, Sabine ^{[5
]}

Van Roy, Nadine ^{[14
]}

Vicha, Ales ^{[27
,28
]}

Chesler, Louis ^{[29
]}

Balwierz, Walentyna ^{[30
]}

Castel, Victoria ^{[31
]}

Elliott, Martin ^{[32
]}

Kogner, Per ^{[33
]}

Laureys, Genevieve ^{[34
]}

Luksch, Roberto ^{[35
]}

Malis, Josef ^{[27
,28
]}

Popovic-Beck, Maja ^{[24
,36
]}

Ash, Shifra ^{[37
]}

Delattre, Olivier ^{[2
,3
,6
]}

Valteau-Couanet, Dominique ^{[38
]}

Tweddle, Deborah A. ^{[39
]}

Ladenstein, Ruth ^{[40
,41
]}

Schleiermacher, Gudrun ^{[1
,2
,3
]}

机构：

[1] Inst Curie, Equipe SiR RTOP Rech Translat Oncol Pediat, Paris, France

[2] Inst Curie, Lab Genet & Biol Canc, INSERM U830, Paris, France

[3] Inst Curie, SIREDO Care Innovat & Res Children Adolescents &, Paris, France

[4] Dept Studies & Stat & Integrated Res, Vienna, Austria

[5] St Anna Childrens Canc Res Inst, Vienna, Austria

[6] Inst Curie, Inst Curie Genom Excellence ICGex Platform, Res Ctr, Paris, France

[7] Inst Curie, Hosp Grp, Serv Genet, Unite Genet Somat, Paris, France

[8] Serv Genet Tumeurs, Villejuif, France

[9] Inst Gustave Roussy, Villejuif, France

[10] Univ Oslo, Oslo Univ Hosp, Dept Pathol, Oslo, Norway

[11] Univ Oslo, Med Fac, Oslo, Norway

[12] Childrens Hlth Ireland Crumlin, Dept Clin Genet, Dublin, Ireland

[13] Newcastle upon Tyne Hosp NHS Fdn Trust, Northern Genet Serv, Newcastle Upon Tyne, Tyne & Wear, England

[14] Univ Ghent, Ghent, Belgium

[15] Ctr Leon Berard, Translat Res Lab, Lyon, France

[16] Inst Invest Sanitaria La Fe, Valencia, Spain

[17] Inst Canc Res, Div Clin Studies, London, England

[18] Tel Aviv Univ, Schneider Childrens Med Ctr Israel, Tel Aviv, Israel

[19] Inst Nacl Saude Doutor Ricardo Jorge, Dept Genet Humana, Lisbon, Portugal

[20] Sahlgrens Univ Hosp, Gothenburg, Sweden

[21] IRCCS Ist Giannina Gaslini, Dept Pathol, Genoa, Italy

[22] IRCCS Ist Giannina Gaslini, Lab Mol Biol, Genoa, Italy

[23] Lausanne Univ Hosp, Pediat Hematol Oncol Res Lab, Lausanne, Switzerland

[24] Univ Lausanne, Lausanne, Switzerland

[25] Univ Valencia, Med Sch, Dept Pathol, Incl Hlth Res Inst CIBERONC, Madrid, Spain

[26] Copenhagen Univ Hosp, Rigshosp, Ctr Genom Med, Copenhagen, Denmark

[27] Charles Univ Prague, Fac Med 2, Dept Paediat Haematol & Oncol, Prague, Czech Republic

[28] Univ Hosp Motol, Prague, Czech Republic

[29] Inst Canc Res, Div Clin Studies, Paediat Tumour Biol, Sutton, Surrey, England

[30] Jagiellonian Univ Med Coll, Inst Pediat, Dept Pediat Oncol & Hematol, Krakow, Poland

[31] Hlth Res Inst La Fe, Clin & Translat Oncol Res Grp, Valencia, Spain

[32] Leeds Childrens Hosp, Leeds Gen Infirm, Leeds, W Yorkshire, England

[33] Karolinska Univ Hosp, Stockholm, Sweden

[34] Ghent Univ Hosp, Princess Elisabeth Childrens Hosp, Dept Paediat Haematol & Oncol, Ghent, Belgium

[35] Ist Nazl Tumori, Fdn IRCCS, Paediat Oncol, Milan, Italy

[36] Lausanne Univ Hosp, Pediat Hematol Oncol Unit, Lausanne, Switzerland

[37] Ruth Rappaport Childrens Hosp, Rambam Hlth Care Campus, Haifa, Israel

[38] Gustave Roussy, Dept Oncol Pediat, Villejuif, France

[39] Newcastle Univ, Wolfson Childhood Canc Res Ctr, Newcastle Ctr Canc, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England

[40] St Anna Childrens Hosp, St Anna Childrens Canc Res Inst, Dept Studies & Stat & Integrated Res, Vienna, Austria

[41] Med Univ Vienna, Dept Paediat, Vienna, Austria

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 30期

关键词：

SEGMENTAL CHROMOSOMAL ALTERATIONS; ACTIVATING MUTATIONS; PEDIATRIC-PATIENTS; CRIZOTINIB; REVEALS; RELAPSE; KINASE; REARRANGEMENTS; HETEROGENEITY; CHEMOTHERAPY;

D O I：

10.1200/JCO.21.00086

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact. MATERIALS AND METHODS Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n = 330), ALK mutational profile (n = 191), or both (n = 571). RESULTS Genomic ALK amplification (ALKa) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALKa was associated with a significantly poorer overall survival (OS) (5-year OS: ALKa [n = 41] 28% [95% CI, 15 to 421; no-ALKa [n = 860] 51% [95% CI, 47 to 54], [P < .001]), particularly in cases with metastatic disease. ALK mutations (ALKm) were detected at a clonal level (> 20% mutated allele fraction) in 10% of cases (76 out of 762) and at a subclonal level (mutated allele fraction 0.1%-20%) in 3.9% of patients (30 out of 762), with a strong correlation between the presence of ALKm and MNA (P< .001). Among 571 cases with known ALKa and ALKm status, a statistically significant difference in OS was observed between cases with ALKa or clonal ALKm versus subclonal ALKm or no ALK alterations (5-year OS: ALKa En = 19], 26% [95% CI, 10 to 47], clonal ALKm En = 65] 33% [95% CI, 21 to 44], subclonal ALKm (n = 22) 48% [95% CI, 26 to 67], and no alteration En = 465], 51% [95% CI, 46 to 55], respectively; P = .001). Importantly, in a multivariate model, involvement of more than one metastatic compartment (hazard ratio [HR], 2.87; P < .001), ALKa (HR, 2.38; P = .004), and clonal ALKm (HR, 1.77; P = .001) were independent predictors of poor outcome. CONCLUSION Genetic alterations of ALK (clonal mutations and amplifications) in HR-NB are independent predictors of poorer survival. These data provide a rationale for integration of ALK inhibitors in upfront treatment of HR-NB with ALK alterations. (C) 2021 by American Society of Clinical Oncology

引用

页码：3377 / +

页数：28

共 50 条

[41] Impact of radiotherapy for high-risk neuroblastoma: A children's cancer group study
Haas-Kogan, DA
Swift, PS
Selch, M
Haase, GM
Seeger, RC
Gerbing, RB
Stram, DO
Matthay, KK
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01): : 28 - 39
[42] MOLECULAR PROFILING INCLUDING GENOMIC ABERRATIONS CAN REVEAL ULTRA HIGH-RISK GROUP IN THE JAPAN NEUROBLASTOMA STUDY GROUP'S CLINICAL TRIAL FOR HIGH-RISK NEUROBLASTOMA
Matsumoto, K.
Ohira, M.
Kamijo, T.
Shichino, H.
Kuroda, T.
Hishiki, T.
Soejima, T.
Kaneko, T.
Nakazawa, A.
Takimoto, T.
Fukushima, T.
Hara, J.
Kaneko, M.
Ikeda, H.
Tajiri, T.
Nakagawara, A.
PEDIATRIC BLOOD & CANCER, 2015, 62 : S225 - S225
[43] High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European neuroblastoma study group
Pritchard, J
Cotterill, SJ
Germond, SM
Imeson, J
de Kraker, J
Jones, DR
PEDIATRIC BLOOD & CANCER, 2005, 44 (04) : 348 - 357
[44] A RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA AFTER 1ST RECURRENCE: A REPORT FROM THE JAPAN NEUROBLASTOMA STUDY GROUP
Hara, Junichi
Takimoto, Tetsuya
Shichino, Hiroyuki
Matsumoto, Kimikazu
Kuroda, Tatsuo
Hishiki, Tomoro
Soejima, Toshinori
Hashii, Yoshiko
Mori, Tetsuya
Ikeda, Hitoshi
PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1059 - 1059
[45] Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.
Ladenstein, Ruth Lydia
Poetschger, Ulrike
Valteau-Couanet, Dominique
Gray, Juliet
Luksch, Roberto
Balwierz, Walentyna
Castel, Victoria
Ash, Shifra
Popovic, Maja Beck
Laureys, Genevieve
Chan, Godfrey Chi Fung
Ruud, Ellen
Vettenranta, Kim
Owens, Cormac
Schroeder, Henrik
Loibner, Hans
Ambros, Peter F.
Sarnacki, Sabine
Boterberg, Tom
Lode, Holger N.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[46] Prognostic impact of I-123-mIBG scintigraphy on survival in patients with stage 4 neuroblastoma > 1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
Schmidt, M.
Simon, T.
Hero, B.
Berthold, F.
Schicha, H.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S144 - S144
[47] A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11
Yoneda, Akihiro
Shichino, Hiroyuki
Hishiki, Tomoro
Matsumoto, Kimikazu
Ohira, Miki
Kamijo, Takehiko
Kuroda, Tatsuo
Soejima, Toshinori
Nakazawa, Atsuko
Takimoto, Tetsuya
Yokota, Isao
Teramukai, Satoshi
Takahashi, Hideto
Fukushima, Takashi
Hara, Junichi
Kaneko, Michio
Ikeda, Hitoshi
Tajiri, Tatsuro
Mugishima, Hideo
Nakagawara, Akira
PEDIATRIC BLOOD & CANCER, 2024, 71 (06)
[48] A safety and feasibility trial of 131I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study
Weiss, Brian D.
Yanik, Gregory
Naranjo, Arlene
Zhang, Fan F.
Fitzgerald, Wendy
Shulkin, Barry L.
Parisi, Marguerite T.
Russell, Heidi
Grupp, Stephan
Pater, Luke
Mattei, Peter
Mosse, Yael
Lai, Hollie A.
Jarzembowski, Jason A.
Shimada, Hiroyuki
Villablanca, Judith G.
Giller, Roger
Bagatell, Rochelle
Park, Julie R.
Matthay, Katherine K.
PEDIATRIC BLOOD & CANCER, 2021, 68 (10)
[49] Long-Term Results for Children with High-Risk Neuroblastoma Treated on the Randomized High-Dose Therapy Trial of Busulphan-Melphalan Versus Carboplatin-Etoposide-Melphalan: A Siopen Study
Ladenstein, R.
Poetschger, U.
Brock, P.
Luksch, R.
Castel, V.
Yaniv, I.
Papadakis, V.
Laureys, G.
Malis, J.
Balwierz, W.
Kogner, P.
Ambros, P.
Holmes, K.
Gaze, M.
Schreier, G.
Garaventa, A.
Vassal, G.
Michon, J.
Pearson, A.
Valteau-Couanet, D.
PEDIATRIC BLOOD & CANCER, 2016, 63 : S32 - S32
[50] Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACONNeuroblastoma randomized phase 2 trial A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.
Moreno, Lucas
Moroz, Veronica
Owens, Cormac
Laidler, Jennifer
Valteau-Couanet, Dominique
Gambart, Marion
Castel, Victoria
Van Eijkelenburg, Natasha
Castellano, Aurora
Nysom, Karsten
Gerber, Nicolas U.
Laureys, Genevieve
Ladenstein, Ruth Lydia
Makin, Guy
Vaidya, Sucheta
Thebaud, Estelle
Kearns, Pamela
Pearson, Andrew D. J.
Wheatley, Keith
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →